nach oben

Medical Oncology

Erschienen in:

01.12.2009 | Original Paper

Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia

verfasst von: M. Braoudaki, M. Karpusas, K. Katsibardi, Ch. Papathanassiou, K. Karamolegou, F. Tzortzatou-Stathopoulou

Erschienen in: Medical Oncology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

FLT3 mutations are occasionally observed in acute lymphoblastic leukemia (ALL). These most frequently manifest as internal tandem duplications (ITD) and activation loop (AL) mutations. This study investigated the incidence of FLT3 mutations in 86 pediatric patients diagnosed with ALL and the co-presence of common RAS mutations. A 2.3% (2/86) FLT3/AL mutation rate in terms of total ALL cases and a 22% (2/9) incidence in hyperdiploid cases was observed. This is in accordance to previous studies indicating a higher incidence in the patient subgroup associated with hyperdiploidy.

Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–42. doi:10.1182/blood-2002-02-0492.CrossRefPubMed

Brown P, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood. 2005;105(2):812–20. doi:10.1182/blood-2004-06-2498.CrossRefPubMed

Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911–8.PubMed

Abu-Duhier FM, et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukemia. Br J Haematol. 2001;113(4):983–8. doi:10.1046/j.1365-2141.2001.02850.x.CrossRefPubMed

Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103(9):3544–6. doi:10.1182/blood-2003-07-2441.CrossRefPubMed

Paulsson K, et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2008;47(1):26–33. doi:10.1002/gcc.20502.CrossRefPubMed

Taketani T, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103(3):1085–8. doi:10.1182/blood-2003-02-0418.CrossRefPubMed

Kiyoi H, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(9):1447–52. doi:10.1038/sj.leu.2400756.CrossRefPubMed

Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–9. doi:10.1182/blood.V97.8.2434.CrossRefPubMed

10.

Auewarakul CU, Lauhakirti D, Tocharoentanaphol C. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. Eur J Haematol. 2006;77(1):51–6.

11.

Liang DC, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 2006;106(4):950–6. doi:10.1002/cncr.21687.CrossRefPubMed

12.

Perentesis JP, et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia. 2004;18(4):685–92. doi:10.1038/sj.leu.2403272.CrossRefPubMed

13.

Andersson A, et al. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns. Genes Chromosomes Cancer. 2008;47(1):64–70. doi:10.1002/gcc.20508.CrossRefPubMed

14.

Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006;178–84.

15.

Grundler R, et al. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005;105(12):4792–9. doi:10.1182/blood-2004-11-4430.CrossRefPubMed

16.

Kiyoi H, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074–80.PubMed

Titel: Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia
verfasst von: M. Braoudaki
M. Karpusas
K. Katsibardi
Ch. Papathanassiou
K. Karamolegou
F. Tzortzatou-Stathopoulou
Publikationsdatum: 01.12.2009
Verlag: Humana Press Inc
Erschienen in: Medical Oncology / Ausgabe 4/2009
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-008-9146-z

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia

Abstract

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Costims – das nächste heiße Ding in der Krebstherapie?

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Matrilysin: a rapidly expanding role in the etiopathogenesis of systemic malignancies

Quality of life, anxiety and depression in Turkish breast cancer patients and in their husbands

Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy

Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection

Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA

The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Costims – das nächste heiße Ding in der Krebstherapie?

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie